Literature DB >> 28855396

Increased adaptive immune responses and proper feedback regulation protect against clinical dengue.

Etienne Simon-Lorière1,2, Veasna Duong3, Ahmed Tawfik1,2, Sivlin Ung4, Sowath Ly5, Isabelle Casadémont1,2, Matthieu Prot1,2, Noémie Courtejoie1,2, Kevin Bleakley6,7, Philippe Buchy3,8, Arnaud Tarantola5,8, Philippe Dussart3, Tineke Cantaert9, Anavaj Sakuntabhai10,2.   

Abstract

Clinical symptoms of dengue virus (DENV) infection, the most prevalent arthropod-borne viral disease, range from classical mild dengue fever to severe, life-threatening dengue shock syndrome. However, most DENV infections cause few or no symptoms. Asymptomatic DENV-infected patients provide a unique opportunity to decipher the host immune responses leading to virus elimination without negative impact on an individual's health. We used an integrated approach of transcriptional profiling and immunological analysis to compare a Cambodian population of strictly asymptomatic viremic individuals with clinical dengue patients. Whereas inflammatory pathways and innate immune response pathways were similar between asymptomatic individuals and clinical dengue patients, expression of proteins related to antigen presentation and subsequent T cell and B cell activation pathways was differentially regulated, independent of viral load and previous DENV infection history. Feedback mechanisms controlled the immune response in asymptomatic viremic individuals, as demonstrated by increased activation of T cell apoptosis-related pathways and FcγRIIB (Fcγ receptor IIB) signaling associated with decreased anti-DENV-specific antibody concentrations. Together, our data illustrate that symptom-free DENV infection in children is associated with increased activation of the adaptive immune compartment and proper control mechanisms, leading to elimination of viral infection without excessive immune activation, with implications for novel vaccine development strategies.
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28855396     DOI: 10.1126/scitranslmed.aal5088

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  36 in total

1.  Micronutrients, Immunological Parameters, and Dengue Virus Infection in Coastal Ecuador: A Nested Case-Control Study in an Infectious Disease Surveillance Program.

Authors:  Julia L Finkelstein; Susannah Colt; Alexander J Layden; Jesse T Krisher; Anna M Stewart-Ibarra; Mark Polhemus; Efraín Beltrán-Ayala; Julia M Tedesco; Washington B Cárdenas; Timothy Endy; Saurabh Mehta
Journal:  J Infect Dis       Date:  2020-01-01       Impact factor: 5.226

Review 2.  Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?

Authors:  Jinsheng Wen; Sujan Shresta
Journal:  Curr Opin Immunol       Date:  2019-03-15       Impact factor: 7.486

Review 3.  T Cell Immunity to Zika and Dengue Viral Infections.

Authors:  Jinsheng Wen; Sujan Shresta
Journal:  J Interferon Cytokine Res       Date:  2017-11       Impact factor: 2.607

4.  Antibody-Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections.

Authors:  Jesse J Waggoner; Leah C Katzelnick; Raquel Burger-Calderon; Julia Gallini; Renee H Moore; Guillermina Kuan; Angel Balmaseda; Benjamin A Pinsky; Eva Harris
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

Review 5.  The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection.

Authors:  Leah C Katzelnick; Eva Harris
Journal:  Curr Opin Virol       Date:  2018-03-26       Impact factor: 7.090

6.  Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers.

Authors:  Stephen J Popper; Fiona R Strouts; Janet C Lindow; Henry K Cheng; Magelda Montoya; Angel Balmaseda; Anna P Durbin; Stephen S Whitehead; Eva Harris; Beth D Kirkpatrick; David A Relman
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

7.  Antibody fucosylation predicts disease severity in secondary dengue infection.

Authors:  Tineke Cantaert; Jeffrey V Ravetch; Stylianos Bournazos; Hoa Thi My Vo; Veasna Duong; Heidi Auerswald; Sowath Ly; Anavaj Sakuntabhai; Philippe Dussart
Journal:  Science       Date:  2021-06-04       Impact factor: 47.728

8.  Antibody-dependent enhancement of severe dengue disease in humans.

Authors:  Leah C Katzelnick; Lionel Gresh; M Elizabeth Halloran; Juan Carlos Mercado; Guillermina Kuan; Aubree Gordon; Angel Balmaseda; Eva Harris
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

9.  Serum Cytokine Profiles in Patients with Dengue Fever at the Acute Infection Phase.

Authors:  Junyuan Huang; Weiwen Liang; Shaoyan Chen; Ye Zhu; Haiming Chen; Chris Ka Pun Mok; Yingchun Zhou
Journal:  Dis Markers       Date:  2018-01-30       Impact factor: 3.434

Review 10.  Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development.

Authors:  Claude Roth; Félix G Delgado; Etienne Simon-Lorière; Anavaj Sakuntabhai
Journal:  Int J Environ Res Public Health       Date:  2018-02-23       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.